secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-005094
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics reports Q4 2022 net loss of $45M; paltusotine Phase 3 data expected 3Q23 and 1Q24
--------------------------------------------------------------------------------

- Net loss $45.0M for Q4 2022 vs $30.8M in Q4 2021; full-year net loss $163.9M vs $107.6M.
- R&D expenses $37.0M in Q4 2022, up from $24.6M; full-year $130.2M vs $84.3M.
- Cash, equivalents, and investments $334.4M as of Dec 31, 2022; company expects runway through 2024.
- Paltusotine Phase 3 PATHFNDR-1 topline data expected 3Q23; PATHFNDR-2 data now expected 1Q24.
- NDA submission for paltusotine in acromegaly planned for 2024 pending positive Phase 3 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017023005094/0000950170-23-005094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017023005094/crnx-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer